Investigates the Role of PANoptosis in Idiopathic Pulmonary Fibrosis and Potential Therapeutic Targets by Xiang Y, Huang G, Luo C, Jiang J, Zhang T, Zeng Q, Zhou F, Du D

Subjects: Get full text

18 F-FLT-PET for response evaluation of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with solid tumors by Ingrid Desar, Rozemarie Gilles, Carla van Herpen, Anja J. Timmer-Bonte, Mireille Cantarini, Winette van der Graaf, Wim Oyen

Subjects: Get full text

Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: insights from FAERS by Lin Li

Subjects: “…selumetinib…”
Get full text

Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma by Erin E. Crotty, Aimee A. Sato, Aimee A. Sato, Mohamed S. Abdelbaki

Subjects: Get full text

Selumetinib in Adult Neurofibromatosis 1 with Plexiform Neurofibroma by Carlen A. Yuen, Eleanor Chu, Ryan O’Connell, Bryan K. Sun, Raj Vyas, Michelle Zheng, Emma Elliott, Changrui Xiao

Subjects: Get full text

Therapeutic drug monitoring of selumetinib in pediatrics: a combined LC-MS/MS and LC-HRMS approach by Alessia Cafaro, Andrea Santangelo, Andrea Santangelo, Sebastiano Barco, Corinna Corsini, Roberto Bandettini, Pasquale Striano, Pasquale Striano, Maria Cristina Diana, Giuliana Cangemi

Subjects: Get full text

Prospects for diagnostics and treatment of neurofibromatosis type 1 in Russia by R. N. Mustafin

Subjects: Get full text

Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management by A. M. Pivovarova, M. Yu. Dorofeeva, A. R. Zabrodina, S. V. Bochenkov, A. V. Grigoryeva, Z. K. Gorchkhanova, V. R. Voronina

Subjects: Get full text